poly(ADP-ribose) polymerase family member 6Genealiases: ARTD17 · PARP-6-B1 · PARP-6-C · pART17
Q-omics provides the consensus-scored PARP6 profile across patient tissues and cancer cell-line models. PARP6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, PARP6 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PARP6 RNA expression shows 18,976 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, KIRC, and UVM as cancer lineages where PARP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARP6 survival associations across molecular data types. PARP6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARP6 RNA expression–survival associations across cancer types. High PARP6 expression shows unfavorable associations in COAD, KIRC, LUSC, KICH and ACC, but favorable associations in UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for PARP6 RNA expression.
This table summarizes PARP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PARP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARP6 shows higher tumor expression in KIRC, HNSC, UCEC, COAD, LUSC and CHOL. The KIRC box plot shows higher PARP6 RNA expression in tumor versus normal tissue (log2 FC = +1.036, t-test p < 0.001).
This table shows molecular features associated with PARP6 in patient tissues and cancer cell lines. In patient samples, PARP6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PARP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
